Collaborative Solutions for Environmental Challenges and Economic Growth

In today’s dynamic landscape of environmental challenges and economic imperatives, the need for collaboration between governments and corporations has never been more urgent. In this in-depth exploration, we delve into Dr. Basil Lui’s visionary insights and initiatives, shedding light on the transformative efforts underway at the intersection of sustainability and economic development.

 

The Emergence of the Singapore Carbon Exchange

Dr. Lui highlights on the establishment of the Singapore Carbon Exchange, a groundbreaking initiative aimed at mitigating carbon emissions through innovative partnerships between government entities and corporations. This platform, driven by collaborative efforts involving prominent stakeholders such as DBS, SGX, and Temasek, marks a paradigm shift in our approach to environmental sustainability.

The core mission of the Singapore Carbon Exchange is to offset carbon emissions by leveraging carbon-negative resources in developing countries, with a particular focus on initiatives centered on forest preservation and regeneration. Through the utilization of cutting-edge technologies like blockchain, the exchange ensures transparency and integrity in carbon offset transactions, laying the foundation for a more sustainable future.

 

Investing in Sustainable Solutions

Dr. Lui’s visionary leadership extends beyond carbon offsetting, encompassing a diverse array of investment practices geared towards sustainability and environmental stewardship. One such investment is in the burgeoning field of lab-grown meat, which holds immense promise for reducing the carbon footprint associated with traditional meat production.

Furthermore, Dr. Lui advocates for investment in synthetic palm oil production as a means of mitigating the environmental impact of palm oil plantations, which have been implicated in deforestation and habitat destruction. By embracing sustainable alternatives, we not only addresses pressing environmental concerns but also lay the groundwork for a more resilient and equitable future.

 

Harnessing the Power of Precision Medicine for Healthcare Optimization

In addition to his efforts in the realm of environmental sustainability, Dr. Lui is also a proponent of leveraging innovative technologies to optimize healthcare resources and enhance patient outcomes. One area of focus is precision medicine, where advancements in genome sequencing hold the potential to revolutionize healthcare delivery.

By leveraging genetic data to inform more targeted medication orders, precision medicine has the potential to reduce waste and healthcare costs while maximizing efficacy and patient satisfaction. Dr. Lui’s advocacy for the integration of precision medicine into mainstream healthcare reflects Singapore’s commitment to harnessing the power of innovation for the betterment of society.

 

Driving Sustainable Change: Towards a Resilient Future

Dr. Basil Lui highlights driving transformative change at the nexus of environmental sustainability, economic growth, and innovation. Through initiatives such as the Singapore Carbon Exchange and investments in sustainable solutions like lab-grown meat and precision medicine, we can pave the way for a more sustainable and prosperous future.

As we navigate the complex challenges of the 21st century, our collaborative approach will be demonstrating the profound impact that can be achieved through partnerships between governments, corporations, and civil society. By harnessing the power of innovation and collective action, we can build a more resilient and sustainable world for generations to come.

 

About Dr. Basil Lui

Dr. Basil Lui is the Founding Partner of AGP. Prior to this, he was an Advisor and Managing Partner at EDBI where he oversaw investments in Healthcare and Emerging Technologies. Dr. Lui was a key member of EDBI’s Investment Committee for ~50 investments with 10 exits. On the healthcare front, he was involved in several investments for EDBI, including Doctor Anywhere a full-stack online-offline healthcare service; Hummingbird Bioscience a clinical-stage precision medicine company; MiRXES a developer of RNA early disease detection tests; US2.ai an AI software platform for echocardiography to fight heart disease; and a pre-covid investment into mRNA vaccine platform Moderna (NASDAQ:MRNA). Basil has a strong interest in regenerative technologies that can restore cellular health and resilience.

Additionally, Dr. Lui drove early stage deep-tech fund-of-funds investments at EDBI, covering regional healthcare funds, and as a LPAC member in portfolio funds, worked closely in partnership with funds to invest in Singapore and the region. He also spearheaded EDBI’s investments in areas that would have an impact to the future of healthcare and the bioeconomy such as synthetic biology, gene edits, robotics, AI, blockchain, AR and VR. Dr. Lui pioneered EDBI’s post-investment value creation and communications efforts, ensuring strong support to portfolio companies through market access, talent recruitment, strategic financing, partnership & guidance; and is often a speaker in global technology events and panels.

Prior to EDBI, Dr. Lui was a McKinsey consultant covering South East Asia, an Adjunct Associate Professor at the Keppel-NUS Corporate Laboratory, the APAC President of a global semiconductor electronic design automation company, an Assistant Professor at National University of Singapore Electrical & Computer Engineering, and a post-doctoral researcher at the Cambridge University Engineering Department. Basil is the inventor of several patents and holds a BA (1st class), MA and PhD from the University of Cambridge. He was awarded a Commonwealth scholarship, a Singapore Government Public Service Commission scholarship, and a Research Fellowship from Trinity College Cambridge.

 

About EDBI 

Investing since 1991, EDBI is a Singapore-based global investor in select high-growth technologies spanning sectors across Information & Communication Technology, Emerging Technology and Healthcare. As a value-creating investor, we support companies aiming to expand in Asia and globally through Singapore with our extensive network, resources and expertise. For more information, visit www.edbi.com.

 

About August Global Partners

August Global Partners (AGP) is an independent fund management company spun out from EDBI, a Singapore state-owned strategic fund, with former top and senior executives as the fund’s founders. Armed with a robust track record and years of success, and having managed significant assets-under-management (AUM) previously, this team will now manage two funds, the AGP Continuation Growth Fund (AGPCG) and a second fund, the AGP Healthcare Fund (AGPHC), to capture new and exciting opportunities. AGPHC is a pure commercially driven fund with Living Better and Aging Better themes.

For more information, visit www.augustglobalpartners.com